Danish drugmaker Novo Nordisk said on Monday several hundred counterfeit units of its diabetes drug Ozempic were being distributed outside its authorized supply chain in the United States. The country's health regulator seized the counterfeit injections on April 9 and is investigating them.

The maker of Ozempic and federal regulators are sending out warnings about counterfeit versions of the anti-diabetic drug after several hundred fake units were seized outside the authorized supply chain.

Several hundred units of counterfeit Ozempic (semaglutide) injection 1 mg have been found in the United States. The FDA seized the counterfeit products on April 9, 2025, and both Novo Nordisk and the FDA are testing the seized products' identify, safety and quality.